Abstract
We designed a platform model that integrates physiologically-based pharmacokinetic (PBPK) modeling with quantitative systems pharmacology (QSP) to bridge translational challenges in antibody-drug conjugate (ADC) development. The PBPK-QSP platform model was developed for the ADC trastuzumab emtansine (T-DM1) in breast cancer patients. This mechanistic framework facilitates translation across preclinical in vitro experiments, in vivo studies, and clinical trials, supporting decision-making for novel ADCs. The PBPK-QSP model adequately predicts preclinical and clinical PK and PD data from two additional ADCs: trastuzumab deruxtecan (T-Dxd) and tusamitamab ravtansine. For within-target validation with T-Dxd in breast cancer, despite extensive preclinical calibration, efficacy predictions were initially overly optimistic compared to T-DM1 validation experience with the model and aggregated phase II trial data. Individual patient data from a phase II T-Dxd trial allowed evaluation of model performance and quantification of translational uncertainty in predicting clinical outcomes using preclinical experiments. Cross-pathway validation with tusamitamab ravtansine in non-small cell lung cancer has revealed the importance of incorporating a resistance module to describe clinical efficacy adequately. Clinical trial simulations for tusamitamab ravtansine subsequently inform that alternative fractional dosing could offer a potential efficacy advantage compared to existing clinical dosing. We integrated these insights into a practical recommended workflow for translational development programs, which addresses the key challenges in parameter estimation, data requirements, and uncertainty quantification in the key system parameters for each indication and cancer type. Ultimately, integrating an interactive modeling platform with a structured workflow to mitigate the risks of human translation and to potentially improve the clinical benefits of novel ADCs in oncology drug development.
Competing Interest Statement
A.D.M. and I.L.-E declare no conflicts of interest, or other competing interests that might be perceived to influence the results and/or discussion reported in this paper. S.-L.C. and D.V. are employees of Sanofi and may hold Sanofi stock and/or stock options.
Funding Statement
This research was funded as an award-winning project in the Sanofi iDEA-TECH Awards Europe 2023 entitled 'Multi-approach Analysis staGe for model-Informed development of drug-Conjugated antiBodies with Updates (Live and via Liberal software) on Expected Treatment outcomes, MAGIC-BULLET'.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This publication also used original trial data provided by the data contributors Hoffmann-LaRoche and Daiichi-Sankyo via Vivli Inc. The data request (Vivli ID: 00009229) included an ethical review as standard. Vivli has not contributed to or approved, and is not in any way responsible for, the contents of this publication.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
For trastuzumab-based ADCs, this publication is partly based on research data from data contributors Daiichi Sankyo and Roche that has been made available through Vivli, Inc. Vivli has not contributed to or approved, and is not in any way responsible for, the contents of this publication. For cross-pathway validation with SAR408701 (tusamitamab ravtansine), we thankfully acknowledge the provision of data from the ADC development at Sanofi, which are not publicly available, though.
